The risk of narrow protection
A peptide can be used, for example, as a vaccine, while an oligonucleotide can be used to silence a given gene whose expression product is involved in the development of a disease. Normally, biotechnology patent applications disclose a high number of peptides or oligonucleotides. The applicant usually follows this strategy in order to reduce the filing costs by gathering several peptides/oligonucleotides in a single application.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
